Editor’s note: The headline and body of this story have been update to correct the name of Eli Lilly’s drug tirzepatide. In support of expectations for Eli Lilly And Company (NYSE:LLY)’s tirzepatide, BMO Capital Markets is tracking weekly Mounjaro, Zepbound, GLP-1 category TRx (total prescriptions), and NRx (new prescriptions). The analyst models $12.78 billion for the fiscal year 2024 tirzepatide revenues. Mounjaro, for diabetes, scripts grew to 313,019 TRx (+5.4% WoW); Zepbound, for weight loss, was 56,095 (+11.8% WoW). Overall, the incretin market grew +3.3% WoW, driven by Zepbound and Moun…
